TherapeuticsMD, Inc.
TXMD
$2.21
-$0.03-1.34%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 869.00K | 724.00K | 893.00K | 784.00K | 952.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 869.00K | 724.00K | 893.00K | 784.00K | 952.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 869.00K | 724.00K | 893.00K | 784.00K | 952.00K |
| SG&A Expenses | 1.05M | 836.00K | 1.77M | 984.00K | 1.18M |
| Depreciation & Amortization | 95.00K | 94.00K | 97.00K | 96.00K | 96.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.15M | 930.00K | 1.86M | 1.08M | 1.27M |
| Operating Income | -280.00K | -206.00K | -969.00K | -296.00K | -319.00K |
| Income Before Tax | 164.00K | 103.00K | -580.00K | 50.00K | 545.00K |
| Income Tax Expenses | -- | -- | 32.00K | -- | -- |
| Earnings from Continuing Operations | 164.00K | 103.00K | -612.00K | 50.00K | 545.00K |
| Earnings from Discontinued Operations | -9.00K | -8.00K | -7.00K | 102.00K | 6.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 155.00K | 95.00K | -619.00K | 152.00K | 551.00K |
| EBIT | -280.00K | -206.00K | -969.00K | -296.00K | -319.00K |
| EBITDA | -185.00K | -112.00K | -872.00K | -200.00K | -223.00K |
| EPS Basic | 0.01 | 0.01 | -0.05 | 0.01 | 0.05 |
| Normalized Basic EPS | 0.01 | 0.01 | -0.03 | 0.00 | 0.03 |
| EPS Diluted | 0.01 | 0.01 | -0.06 | 0.01 | 0.05 |
| Normalized Diluted EPS | 0.01 | 0.01 | -0.03 | 0.00 | 0.03 |
| Average Basic Shares Outstanding | 11.57M | 11.57M | 11.58M | 11.57M | 11.57M |
| Average Diluted Shares Outstanding | 11.64M | 11.64M | 11.58M | 11.57M | 11.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |